Digital Affectability

LATEST THINKING

Life Sciences companies can now apply a new approach to assessing the “affectability” (or dollar value) of the economic potential of digital health assets in specific therapeutic areas (TAs) across the patient journey: prevention/early diagnosis, intervention and monitoring.

By assessing digital opportunities and avoidable costs through a TA lens, they can identify hidden pockets of value they have likely overlooked. They can define a value-creation strategy, based on a differentiated portfolio of digital assets. And they can make more strategic investment decisions that help improve patient outcomes, business performance and competitive advantage.

VIEW THE REPORT [PDF]

KEY FINDINGS

Life Sciences companies have not had an effective way to measure the affectability of digital assets on patient outcomes or disease cost burdens.

Until now.

Accenture Strategy used a new approach to analyze digital’s potential economic impact on six therapeutic areas (TAs).

What we found:

Across all six TAs, digital assets present a $108 billion value opportunity (or $60 billion, when adjusted for risk).
The highest-impact digital opportunities often lie outside high-prevalence diseases. In fact, 50 percent of system costs can be avoided by targeting investments to rarer disease states.
Within prevalent disease states, too, the opportunity does not lie where many Life Sciences companies think. The greatest digital value lies in assets that can be applied to multiple TAs. For example, in the area of Congestive Heart Failure, $2 billion in annual costs can be avoided by applying digital assets originally intended for Diabetes, Atrial Fibrillation and Hypertension.

RECOMMENDATIONS

A Digital Potential Analysis allows Life Sciences companies to see the economic impact of digital assets within specific TAs across the patient journey. The therapeutic lens expands these companies’ perspectives and opens up new investment opportunities. To capture the greatest value from their digital assets, Life Sciences companies must:

Make digital asset investment a C-suite imperative.

Implement a digital portfolio investment approach and conduct cross-disease value calculations to scale investments and reduce disease cost burdens.

Build digital ecosystems with other companies to seize more digital value.

Embed digital collaborations as a strategic capability.

LEARN MORE ABOUT ACCENTURE STRATEGY

IMMUNIZE FOR INEFFICIENCY

By Jennifer Donatelli, Kenneth Munie, and Natasha Sunderji

A digital supply network can increase affordable access to medicines and pay for itself.

Fragmented pharmaceutical supply chains in developing countries add price mark-ups and opportunities for counterfeit, leaving doctors, clinics and patients unable to afford or trust the medicine they receive. Solving this problem not only will save lives but will also open up markets for business growth. Digital supply networks provide the visibility and control needed to re-invent the process, ensuring safe and affordable medicines delivered by an approach that saves money while saving lives.

READ IMMUNIZE FOR INEFFICIENCY [PDF]

DOWNLOAD VIDEO TRANSCRIPT [PDF]

Click here to download the full article. Immunize for inefficiency. This opens a new window.

A digital supply network can bring visibility and efficiency into emerging markets by leap-frogging traditional approaches. Pharmaceutical companies and NGOs can save money while improving access to medicine by:

Identifying the best market segments and niches to serve.
Finding the right local and global partners to tap into the market.
Applying technology in new ways to solve problems that are unique to developing economies.

Find out more about how digital supply networks can save lives and generate healthy growth.

“Save lives and money. Digital supply networks add efficiency, affordability, safety and profit in emerging markets”

Tweet This >